Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 9 | 3 | — | 4 | 16 |
B-cell lymphoma | D016393 | — | — | 1 | 9 | 3 | — | 4 | 16 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 4 | 4 | — | — | 8 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 3 | 2 | — | 1 | 5 |
Lymphoid leukemia | D007945 | — | C91 | — | 2 | 2 | — | 1 | 4 |
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | 1 | 3 | 1 | — | — | 4 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 1 | 3 | 1 | — | — | 4 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | 1 | — | — | 3 |
Leukemia | D007938 | — | C95 | — | 1 | 1 | — | — | 2 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 2 | 2 | — | — | — | 3 |
Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | 1 | 3 |
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 1 | — | — | — | 1 |
Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
Waldenstrom macroglobulinemia | D008258 | — | C88.0 | — | 1 | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
Follicular lymphoma | D008224 | — | C82 | — | 1 | — | — | — | 1 |
Hodgkin disease | D006689 | — | C81 | 1 | 1 | — | — | — | 1 |
Central nervous system neoplasms | D016543 | — | — | — | 1 | — | — | — | 1 |
Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | — | — | — | — | 1 | 1 |
Neoplasms by histologic type | D009370 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Orelabrutinib |
INN | orelabrutinib |
Description | Orelabrutinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase BTK. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1 |
PDB | — |
CAS-ID | 1655504-04-3 |
RxCUI | — |
ChEMBL ID | CHEMBL4650321 |
ChEBI ID | — |
PubChem CID | 91667513 |
DrugBank | DB16272 |
UNII ID | WJA5UO9E10 (ChemIDplus, GSRS) |